secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0001396814-23-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira BioSciences reports preliminary 2022 revenue of $666.8M, up 23.1% YoY
----------------------------------------------------------------------------

- EXPAREL net sales $536.9M in 2022 vs $506.5M in 2021; Q4 2022 sales $138.0M, roughly flat vs prior Q4.
- ZILRETTA net sales $105.5M in 2022 vs $12.7M in 2021 (acquired Nov 2021); Q4 2022 sales $28.0M.
- Adjusted EPS expected at least $2.50 for 2022, marking ninth consecutive year of positive adjusted earnings.
- Prepaid $50M on Term Loan B in Dec 2022; plans another significant prepayment in 2023.
- Management cites strong balance sheet, durable cash flows, and outperformance vs surgical market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681423000003/0001396814-23-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681423000003/pcrx-20230105.htm
  HTML page:      https://secwatch.observer/filing/0001396814-23-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer